The verdict
Our read at a glance.
Whether raising NAD-related biomarkers improves clinically meaningful outcomes rather than only changing lab measures.
- The signal
- Randomized human studies support biomarker movement and selected functional signals, but longevity or disease-prevention conclusions are not established.
- The unknown
- Which populations benefit, which endpoints matter, long-term safety, and whether biomarker changes translate into outcomes.
- Our read
- Better human evidence than many longevity compounds, but still often oversold.
The mechanism
How it works.
NAD+ is a coenzyme every cell uses to shuttle electrons during energy metabolism and to fuel repair enzymes. NR and NMN are precursor molecules the body converts into NAD+, so taking them raises the available NAD+ pool, which cells draw on to run mitochondrial energy production and to power sirtuins and PARPs (the enzymes that handle DNA repair and stress responses). In humans these supplements reliably raise NAD+ blood markers, but whether that bump changes how tissues age or function is the part that remains unproven.
Safety & regulatory boundary
The consequential part.
Biomarker movement is not the same as a clinical outcome.
What's next
What we're watching.
Longer trials, clinical endpoints, tissue-specific data, and independent replication.
Context
Why this is discussed.
NAD biology is central to aging narratives, mitochondrial function, and supplement marketing.
The evidence base
3 cited references.
Peer-reviewed journals1
Indexed literature (PubMed)2
Clinical trial authors · 2024
Keep reading